RE:RE:Another fat Dividend The GUD Medison deal is very similar to that of PDP, but of a more substantial nature.
Specifically, Knight hold a 28.3% equity interest in Medison valued at $80 million [US$60 million] in exchange for approximately a 10% equity interest in Knight (10.33 million common shares of Knight to be held by Medison and its controlling shareholder).
Jonathan Ross Goodman, President and CEO of Knight, join Medison’s Board of Directors while Meir Jakobsohn, Founder and CEO of Medison, joined the Knight Board of Directors.
Medison is a privately owned company founded in 1995. The company is focused on delivering innovative healthcare solutions to the Israeli and Romanian markets, starting from Early Access Programs to government registration and reimbursement, medical affairs, marketing and logistics
. Medison is the exclusive Israeli partner for leading global pharma companies such as Amgen®, Biogen®, Shire® and Ipsen®.
Medison's is rapidly growing with current sales of approximately $200 million with a portfolio of over 40 unique and innovative products, the vast majority are intended for patients with rare and severe diseases.
Evidence of this is the fact that Medison has increased its dividend in 2016 to $4.8 million from $3.8 million in 2015.
Great synergies produce great companies.
Medison at some point will be fully acquired GUD..